Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

2.

Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.

Deedwania PC, Stone PH, Fayyad RS, Laskey RE, Wilson DJ.

Drugs Aging. 2015 Dec;32(12):1055-65. doi: 10.1007/s40266-015-0328-z.

3.

Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.

Sanguankeo A, Upala S, Cheungpasitporn W, Ungprasert P, Knight EL.

PLoS One. 2015 Jul 7;10(7):e0132970. doi: 10.1371/journal.pone.0132970. eCollection 2015. Review.

4.

High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis.

Yan YL, Qiu B, Wang J, Deng SB, Wu L, Jing XD, Du JL, Liu YJ, She Q.

BMJ Open. 2015 May 15;5(5):e006886. doi: 10.1136/bmjopen-2014-006886. Review.

5.

Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry.

Luczak M, Formanowicz D, Marczak Ł, Pawliczak E, Wanic-Kossowska M, Figlerowicz M, Stobiecki M.

J Transl Med. 2015 Jan 27;13:20. doi: 10.1186/s12967-014-0378-8.

6.

Serum lipid profiles, lipid ratios and Chronic Kidney Disease in a Chinese population.

Zhang L, Yuan Z, Chen W, Chen S, Liu X, Liang Y, Shao X, Zou H.

Int J Environ Res Public Health. 2014 Jul 29;11(8):7622-35. doi: 10.3390/ijerph110807622.

7.

Clinical therapeutic strategies for early stage of diabetic kidney disease.

Kitada M, Kanasaki K, Koya D.

World J Diabetes. 2014 Jun 15;5(3):342-56. doi: 10.4239/wjd.v5.i3.342. Review.

8.

Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.

Zhang X, Xiang C, Zhou YH, Jiang A, Qin YY, He J.

BMC Cardiovasc Disord. 2014 Feb 17;14:19. doi: 10.1186/1471-2261-14-19. Review.

10.

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF.

Ann Intern Med. 2012 Aug 21;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007. Review.

11.

Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).

Ho JE, Waters DD, Kean A, Wilson DJ, Demicco DA, Breazna A, Wun CC, Deedwania PC, Khush KK; TNT Investigators.

Am J Cardiol. 2012 Jun 15;109(12):1761-6. doi: 10.1016/j.amjcard.2012.02.019. Epub 2012 Mar 28.

12.

Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.

Sakaeda T, Kadoyama K, Okuno Y.

PLoS One. 2011;6(12):e28124. doi: 10.1371/journal.pone.0028124. Epub 2011 Dec 20.

13.

Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: a cohort study.

Bansal N, Hsu CY, Chandra M, Iribarren C, Fortmann SP, Hlatky MA, Go AS.

BMC Nephrol. 2011 Sep 14;12:44. doi: 10.1186/1471-2369-12-44.

14.

Dyslipidemia associated with chronic kidney disease.

Tsimihodimos V, Mitrogianni Z, Elisaf M.

Open Cardiovasc Med J. 2011;5:41-8. doi: 10.2174/1874192401105010041. Epub 2011 Feb 24.

15.

Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice.

Yamamoto S, Zuo Y, Ma J, Yancey PG, Hunley TE, Motojima M, Fogo AB, Linton MF, Fazio S, Ichikawa I, Kon V.

Nephrol Dial Transplant. 2011 Aug;26(8):2491-7. doi: 10.1093/ndt/gfq759. Epub 2011 Jan 18.

16.

Reducing morbidity and mortality in high risk patients with statins.

Singh V, Deedwania P.

Vasc Health Risk Manag. 2009;5(2):495-507. Epub 2009 Jun 7. Review.

Items per page

Supplemental Content

Write to the Help Desk